• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

COPD Differs by Sex (and Other Recent Findings)

Slideshow

COPD phenotypes differ by sex and ICS are still overprescribed-2 findings that lead this month’s lung disease research review for primary care.

Possible biomarker of early COPD, inhaled corticosteroids overprescribed, SABA use boosts burden-these are some of the latest developments in chronic obstructive pulmonary disease (COPD) research. Scroll through the slides below to find concise summaries of key points for clinical practice.

Related Content
FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar

FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar

Patient Care Editorial Staff
March 10th 2025
Article

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

Dupilumab Shows Efficacy and Safety in COPD With Type 2 Inflammation: AAAAI 2025

Dupilumab Shows Efficacy and Safety in COPD With Type 2 Inflammation: AAAAI 2025

Patient Care Editorial Staff
March 6th 2025
Article

Investigators concluded that dupilumab reduced exacerbation rates, improved lung function, and decreased systemic corticosteroid use in patients with COPD driven by type 2 inflammation.

Fall Risk Near End of Life in COPD / image credit ©Toa555/shutterstock.com

5 Drug Classes Linked to Increased Fall Risk Among Adults with COPD Near End of Life

Grace Halsey
January 30th 2025
Article
FDA Accepts GSK’s Submission for Use of Mepolizumab in COPD

FDA Accepts GSK’s Submission for Use of Mepolizumab in COPD

Sydney Jennings
December 9th 2024
Article

The Prescription Drug User Fee Act date is set for May 7, 2025.

MeiLan K Han, MD, MS

2025 GOLD Report for COPD: MeiLan Han, MD, MS, Discusses Addition of Dupilumab, Ensifentrine

Grace Halsey
November 19th 2024
Article

The 2 newly approved COPD therapies have been added to the GOLD guidelines section on follow-up therapy, expanding clinical options for specific patient types.

Drug Duo Improves COVID-19 Outcomes: Daily Dose / image credit: ©New Africa/AdobeStock

New Drug Boosts COPD Lung Function, QoL Regardless of Severity: Daily Dose

Sydney Jennings
October 25th 2024
Article

Your daily dose of the clinical news you may have missed.

© 2025 MJH Life Sciences

All rights reserved.